A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer

Sponsor
Beijing Friendship Hospital
Study ID
NCT03271073
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle

Study Details

Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib showed good safety and efficacy as third-line therapy for advanced gastric cancer.We conducted this trial to investigate the safety and efficacy of apatinib combined with S1 after failure of first-line chemotherapy in advanced gastric cancer or gastroesophageal junction carcinoma patients.

Key Dates

Start date
Feb 1, 2016
Status verified
Aug 2017
Primary completion
Jul 31, 2018
Completion
Jan 31, 2019

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus S1
    patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: Approximately 1 year ]

Central Contacts

Related Studies